Algeta wants to pay the Nanostart-holding Lumiphore a fee on signing the option agreement and wants to make further payments should it exercise the option and take up the license, according to Marco Beckmann. Nanostart-holding Lumiphore has, according to Marco Beckmann, other existing partnership with Thermo Fisher Scientific specialty Diagnostics for certain diagnostic tests in both laboratory and point-of-care format, such as for downs syndrome; with CisBio international, for the drug discovery research market; and with Biophor Diagnostics Inc. for diagnostic tests for drugs of abuse. Nano launch AG, headquartered in the German financial capital of Frankfurt, is the world’s leading nanotechnology investment company, with portfolio companies spanning the globe from Silicon Valley to Singapore. Under CEO Marco Beckmann, the company provides venture capital financing for nanotechnology companies in various growth phases, with a focus on innovation-driven industries of the future. Nanostart invests globally and in different stages of enterprises.

Nanostart invests according to Marco Beckmann, either directly into companies funds or regionally through nanotechnology. Marco Beckmann is president of Nanostart Asia. This is the 100-percent subsidiary of nano launch in Singapore. Disclaimer: This notice constitutes neither to offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of nano start AG in conjunction with the existing listing of its shares in the “entry standard” segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the Canada, Australia or Japan.